DECREASED FERRITIN LEVELS IN BRAIN IN PARKINSONS-DISEASE

被引：239

作者：

DEXTER, DT

CARAYON, A

VIDAILHET, M

RUBERG, M

AGID, F

AGID, Y

LEES, AJ

WELLS, FR

JENNER, P

MARSDEN, CD

机构：

[1] UNIV LONDON,PARKINSONS DIS SOC,RES CTR,INST PSYCHIAT,DEPT NEUROL,LONDON,ENGLAND

[2] UNIV LONDON KINGS COLL HOSP,SCH MED,LONDON SE5 8RX,ENGLAND

[3] NATL HOSP,LONDON WC1N 3BG,ENGLAND

[4] HOP LA PITIE SALPETRIERE,INSERM,U289,MED EXPTL LAB,PARIS,FRANCE

来源：

JOURNAL OF NEUROCHEMISTRY | 1990年 / 55卷 / 01期

关键词：

CSF; Ferritin; Human brain; Iron; Parkinson's disease; Serum; Substantia nigra;

D O I：

10.1111/j.1471-4159.1990.tb08814.x

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Abstract: Ferritin levels were measured in postmortem brain tissue from patients dying with Parkinson's disease [treated with L‐3,4‐dihydroxyphenylalanine (L‐DOPA)] and from control patients. Ferritin levels were decreased in the substantia nigra, caudate‐putamen, globus pallidus, cerebral cortex, and cerebellum when compared with age‐matched control tissues. However, in CSF from L‐DOPA‐treated patients and in serum from L‐DOPA‐treated and untreated parkinsonian patients, ferritin levels were normal. Previous studies have suggested an increased total iron content in substantia nigra of parkinsonian brain. The failure of substantia nigra ferritin formation to be stimulated by increased iron levels suggests some defect in iron handling in this critical brain region in Parkinson's disease. The reason for decreased ferritin levels throughout the parkinsonian brain is not clear but does not seem to reflect a general system deficit in ferritin. Copyright © 1990, Wiley Blackwell. All rights reserved

引用

页码：16 / 20

页数：5

共 20 条

[1] DOES LEVODOPA AGGRAVATE PARKINSONS-DISEASE [J].